Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT-Reference-Cited by-同舟云学术

Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT

Published:2018-01-12 Issue:4 Volume:53 Page:422-430
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Cesaro Simone,Crocchiolo Roberto,Tridello Gloria,Knelange Nina,Van Lint Maria Teresa,Koc Yener,Ciceri Fabio,Gülbas Zafer,Tischer Johanna,Afanasyev Boris,Bruno Benedetto,Castagna Luca^ORCID,Blaise Didier^ORCID,Mohty Mohamad,Irrera Giuseppe,Diez-Martin J. L.,Pierelli Luca,Pioltelli Pietro,Arat Mutlu,Delia Mario,Fagioli Franca,Ehninger Gerhard,Aljurf Mahmoud,Carella Angelo Michele,Ozdogu Hakan,Mikulska Malgorzata,Ljungman Per^ORCID,Nagler Arnon,Styczynski Jan

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-017-0016-1.pdf

Reference36 articles.

1. Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Heinsele H, et al. Infectious diseases working party of the European group for blood and marrow transplantation. Donor Cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis. 2014;59:473–81.

2. Sellar RS, Vargas FA, Henry JY, Verfuerth S, Charrot S, Beaton B, et al. CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status. Blood. 2015;125:731–9.

3. Ugarte-Torres A, Hoegh-Petersen M, Liu Y, Zhou F, Williamson TS, Quinlan D, et al. Donor serostatus has an impact on Cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011;17:574–85.

4. Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, et al. Patient Cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol. 2001;113:1060–71.

5. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am. 2010;24:319–37.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell transplant patients at high risk for cytomegalovirus complications: evaluation of vaccine safety, immunogenicity and impact on viremia requiring antivirals;Haematologica;2024-02-29

2. More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses?;Hematology;2024-02-08

3. HLA Haplotypes and Relapse After Hematopoietic Cell Transplantation;Journal of Clinical Oncology;2023-12-05

4. Does PTCY increase the risk of infections?;Blood Reviews;2023-11

5. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study;Frontiers in Immunology;2023-03-03